The National Institute for Health and Care Excellence (NICE) is consulting on draft guidance that recommends against National Health Service (NHS) funding for low-dose atropine eye drops to slow myopia progression in children aged three to 14, citing insufficient evidence regarding value for money.
The draft guidance issued by the National Institute for Health and Care Excellence (NICE) regarding low-dose atropine applies to children in England. While private treatment pathways remain unaffected, the decision leaves families seeking publicly funded interventions for progressive short-sightedness without an NHS route.
In Plain English: The Clinical Takeaway
- What is being decided: NICE has published draft guidance proposing that the NHS should not fund low-dose atropine eye drops for slowing childhood myopia progression.
- Who is affected: Children in England aged three to 14 with a myopia progression rate of 0.50 dioptres (D) or more per year and a severity between -0.50D and -6.00D. Existing NHS treatments started before the draft guidance remain protected.
- What alternatives exist: Families can still access low-dose atropine through private healthcare channels.
The Scope of the NICE Draft Guidance and Clinical Criteria
According to the Association of Optometrists (AOP), the draft guidance specifically targets children in England between the ages of three and 14 who experience a progression rate of 0.50 dioptres or more per year. The clinical threshold for the evaluated population covers children with a severity ranging from -0.50D to -6.00D.
The primary driver behind the NICE draft recommendation is health economics. According to the consultation document, “This is because there is not enough evidence to determine whether low-dose atropine eye drops are value for money in this population.”
| Parameter | Clinical Detail |
|---|---|
| Target Population | Children aged 3 to 14 years in England. |
| Refractive Criteria | Severity of -0.50D to -6.00D with progression of 0.50D/year. |
| Intervention Evaluated | Low-dose atropine eye drops for myopia progression. |
| Proposed NHS Funding Status | Not recommended due to insufficient evidence of cost-effectiveness. |
| Existing NHS Patients | Treatment started prior to guidance publication may continue without funding changes. |
Submissions to the public consultation closed on August 19, 2026. Stakeholders were encouraged to review whether all relevant clinical and cost-effectiveness data had been adequately weighed. Following the publication, professional bodies such as the AOP updated their internal myopia management frameworks to reflect the evolving regulatory stance.
Future Trajectory for Pediatric Vision Care
References
- National Institute for Health and Care Excellence (NICE). Draft Guidance on Low-Dose Atropine for Childhood Myopia. Published August 2026.
- Association of Optometrists (AOP). NICE consults on draft low-dose atropine guidance. Published August 13, 2026.
Disclaimer: This article is for informational purposes only and does not constitute medical, financial, or legal advice. Always consult a qualified healthcare provider for diagnosis and treatment of medical conditions.
